Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Der Pathologe
|
November 10, 2019
[Urachal Cancer: an update of current molecular findings]
H Reis, F Mairinger, S Ting, et al.
Der Urologe. Ausg. A
|
May 4, 2019
[PSA increase after definitive treatment]
T Maurer, B Hadaschik, L Budäus, et al.
Der Urologe. Ausg. A
|
March 12, 2015
[Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications]
R Höfflin, W Roth, H Sültmann, et al.
Der Urologe. Ausg. A
|
May 4, 2016
[Self-concept and erectile dysfunction in 45-year-old men : Results of a corollary study of the PROBASE trial]
A M Kögel, A Dinkel, B Marten-Mittag, et al.
Urologic Oncology
|
October 13, 2020
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy
T Szarvas, A Csizmarik, M Váradi, et al.
Der Urologe. Ausg. A
|
June 20, 2014
[Focal therapy for prostate cancer in Germany - 2014 status]
A Roosen, R Ganzer, B Hadaschik, et al.
Aktuelle Urologie
|
February 7, 2015
[Cancer control in focus insights and future perspectives for the focal treatment of prostate cancer]
M Schostak, J Köllermann, B Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 28, 2016
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Frederik L Giesel, B Hadaschik, J Cardinale, et al.
World Journal of Urology
|
May 6, 2016
Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage
J J Wendler, R Ganzer, B Hadaschik, et al.
Der Urologe. Ausg. A
|
May 31, 2015
[Irreversible electroporation. Current value for focal treatment of prostate cancer]
J J Wendler, R Ganzer, B Hadaschik, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Der Pathologe
|
November 10, 2019
[Urachal Cancer: an update of current molecular findings]
H Reis, F Mairinger, S Ting, et al.
Der Urologe. Ausg. A
|
May 4, 2019
[PSA increase after definitive treatment]
T Maurer, B Hadaschik, L Budäus, et al.
Der Urologe. Ausg. A
|
March 12, 2015
[Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications]
R Höfflin, W Roth, H Sültmann, et al.
Der Urologe. Ausg. A
|
May 4, 2016
[Self-concept and erectile dysfunction in 45-year-old men : Results of a corollary study of the PROBASE trial]
A M Kögel, A Dinkel, B Marten-Mittag, et al.
Urologic Oncology
|
October 13, 2020
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy
T Szarvas, A Csizmarik, M Váradi, et al.
Der Urologe. Ausg. A
|
June 20, 2014
[Focal therapy for prostate cancer in Germany - 2014 status]
A Roosen, R Ganzer, B Hadaschik, et al.
Aktuelle Urologie
|
February 7, 2015
[Cancer control in focus insights and future perspectives for the focal treatment of prostate cancer]
M Schostak, J Köllermann, B Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 28, 2016
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
Frederik L Giesel, B Hadaschik, J Cardinale, et al.
World Journal of Urology
|
May 6, 2016
Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage
J J Wendler, R Ganzer, B Hadaschik, et al.
Der Urologe. Ausg. A
|
May 31, 2015
[Irreversible electroporation. Current value for focal treatment of prostate cancer]
J J Wendler, R Ganzer, B Hadaschik, et al.
Page
of 5